Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Recurrence

Carcinoma

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Disease Attributes

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Ovarian Cancer

Ovarian Epithelial Cancer

All Drugs and Chemicals

Antineoplastic Agents

Antibodies

Olaparib

Antibodies, Bispecific

Immunoglobulins

Poly(ADP-ribose) Polymerase Inhibitors

AK112 injection low dose+ olaparib (Lynparza®) PARP inhibitor

AK112 low dose

AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor

AK112 medium dose

AK112 injection high dose+ olaparib (Lynparza®) PARP inhibitor

AK112 high dose

Lingying Wu, MD

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with PARP inhibitor in patients with recurrent ovarian cancer.

A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

Phase Ib/II Clinical Study of Anti-PD-1 and VEGF Bispecific Antibody (AK112) Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

An AE is any untoward medical occurrence in a subject, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

ORR is the proportion of subjects with complete response(CR) or partial response(PR) assessed according to RECIST v1.1

DCR based on RECIST v1.1. DCR is defined as the proportion of subjects with CR, PR, or SD.

PFS based on RECIST v1.1. PFS is defined as the time from the date of randomization till the first documentation of disease progression assessed by the investigator or death due to any cause (whichever occurs first)

OS based on RECIST v1.1. OS is defined as the time from the date of randomization or first dosing date to death due to any cause

Serum PK concentrations of AK112 in individual subjects at different time points after AK112 administration

Immunogenicity of AK112: Number of subjects with detectable anti-drug antibodies (ADA)

Immunogenicity of AK112: Percentage of subjects with detectable anti-drug antibodies (ADA)

Correlation between PD-L1 and AK112 in tumor tissues

Association between gBRCA1/2 mutation in peripheral blood and antitumor activity of AK112

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer	NCT04999605	Ovarian Neoplas... Recurrent Ovari... Relapsed Ovaria... Ovarian Cancer	AK112 low dose AK112 medium do... AK112 high dose	18 Years - 75 Years	Akeso
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer	NCT04999605	Ovarian Neoplas... Recurrent Ovari... Relapsed Ovaria... Ovarian Cancer	AK112 low dose AK112 medium do... AK112 high dose	18 Years - 75 Years	Akeso

Spots Global Cancer Trial Database for ak112 medium dose